Second big submission for Bayer in Japan as VEGF Trap-Eye lodged for wet AMD
This article was originally published in Scrip
Executive Summary
Bayer HealthCare has made its second big submission in Japan this year, filing for the regulatory approval of VEGF Trap-Eye (aflibercept) for the treatment of wet age-related macular degeneration (AMD).